Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 449 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CIS Clear all
Completed Phase 2 Interventional

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586
View directory record Official record
Conditions
Drug Toxicity, Lung Cancer
Interventions
13-cis retinoic acid, Tocopherol
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
4
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

NCT04985032
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Invasive Ductal Carcinoma of Female Breast
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
RPCR, Inc.
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Phase 2 Interventional Results available

St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer

NCT00110136
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
St. John's Wort
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005847
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant interferon alfa, estramustine phosphate sodium, isotretinoin, mitoxantrone hydrochloride, paclitaxel, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Denver, Colorado • Atlanta, Georgia • Decatur, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 6:30 PM EDT
Recruiting Phase 2 Interventional

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

NCT06185205
View directory record Official record
Conditions
Breast Cancer
Interventions
Accelerated partial breast irradiation
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
45 Years to 79 Years · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 30, 2026, 6:30 PM EDT
Completed No phase listed Observational

Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer

NCT01706432
View directory record Official record
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 30, 2026, 6:30 PM EDT
Not listed Not applicable Interventional

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

NCT00126464
View directory record Official record
Conditions
Breast Cancer
Interventions
fulvestrant, tamoxifen citrate, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Not applicable Interventional

Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer

NCT04871516
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost, Therapeutic Surgical Procedure, Whole Breast Irradiation, Breast MRI
Other · Radiation · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

NCT01905046
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
27
States / cities
Duarte, California • Los Angeles, California • South Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Not applicable Interventional

Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy

NCT02023008
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Fatigue, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
yoga therapy, internet-based intervention, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1 Interventional

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

NCT01140178
View directory record Official record
Conditions
Dysplasia, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy in Treating Patients With Early Esophageal Cancer

NCT00002935
View directory record Official record
Conditions
Esophageal Cancer
Interventions
porfimer sodium
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2011 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Phase 1 Interventional

Wild Type p53 Adenovirus for Oral Premalignancies

NCT00410865
View directory record Official record
Conditions
Mouth Cancer
Interventions
INGN 201
Genetic
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Not applicable Interventional

Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors

NCT04906200
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Best Practice, Internet-Based Intervention, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
15 Years to 39 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Recruiting Phase 2 Interventional

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

NCT05865028
View directory record Official record
Conditions
Oropharyngeal Dysplasia, Oral Cavity Dysplasia, Oral Carcinoma in Situ
Interventions
APG-157
Drug
Lead sponsor
Elizabeth J Franzmann
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 30, 2026, 6:30 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen

NCT05591547
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Radiation
Lead sponsor
Sanford Health
Other
Eligibility
50 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Worthington, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 6:30 PM EDT
Withdrawn Early Phase 1 Interventional

To Evaluate the Characteristics of a Breast Cancer

NCT01055678
View directory record Official record
Conditions
Breast Cancer
Interventions
EF5, Partial or Total Mastectomy
Drug · Procedure
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 30, 2026, 6:30 PM EDT
Not listed No phase listed Observational

Women At Risk: The High Risk Breast Cancer Program

NCT01034891
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2009 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

NCT02365766
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery
Drug · Procedure
Lead sponsor
Jason R. Brown
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 30, 2026, 6:30 PM EDT
No Longer Available No phase listed Expanded access

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

NCT00633373
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 30, 2026, 6:30 PM EDT
Completed No phase listed Observational

Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)

NCT00804128
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Imaging (MRI), Gadavist
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 30, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy

NCT00843167
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
broccoli sprout extract, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 30, 2026, 6:30 PM EDT